Activation of c-Jun N-terminal kinase mediates gp120IIIB-and nucleoside analogue-induced sensory neuron toxicity

被引:38
作者
Bodner, A [1 ]
Toth, PT [1 ]
Miller, RJ [1 ]
机构
[1] Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA
关键词
AIDS; HIV-1; sensory neuron; peripheral neuropathy; gp120; JNK signaling; NRTI; apoptosis; HAART; mixed lineage kinases;
D O I
10.1016/j.expneurol.2004.04.009
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Peripheral neuropathy is the most common neurological symptom in patients with acquired immunodeficiency syndrome (AIDS). Here, we examine possible mechanisms of gp120 and micleoside reverse transcriptase inhibitors (NRTIs) in the pathogenesis of AIDS peripheral neuropathy. Neonatal dorsal root ganglion (DRG) neurons were found to undergo apoptosis in response to chronic treatment with gp120IIIB, an effect enhanced by the co-application of hCD4, as well as upon exposure to the nucleoside reverse transcriptase inhibitor (NRTI), 2,3'-dideoxyinosine (ddI). DRG neurons were rescued from the neurotoxic effects of these agents by CEP-1347, an inhibitor of the mixed lineage kinases (MLKs), upstream activators of the c-Jun N-terminal kinase (JNK) signaling pathway. In addition, gp120- or ddI-mediated toxicity were also inhibited by neuronal expression of dominant negative versions of the MLKs. Our results suggest that both gp120 and the NRTIs cause sensory neuron apoptosis through the activation of the JNK pathway, and that CEP-1347-like compounds may serve as a therapeutic option in patients with AIDS-associated peripheral neuropathy. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:246 / 253
页数:8
相关论文
共 55 条
[1]
A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ABRAMS, DI ;
GOLDMAN, AI ;
LAUNER, C ;
KORVICK, JA ;
NEATON, JD ;
CRANE, LR ;
GRODESKY, M ;
WAKEFIELD, S ;
MUTH, K ;
KORNEGAY, S ;
COHN, DL ;
HARRIS, A ;
LUSKINHAWK, R ;
MARKOWITZ, N ;
SAMPSON, JH ;
THOMPSON, M ;
DEYTON, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) :657-662
[2]
Pathogenesis of human immunodeficiency virus-induced neurological disease [J].
Albright, AV ;
Soldan, SS ;
González-Scarano, F .
JOURNAL OF NEUROVIROLOGY, 2003, 9 (02) :222-227
[3]
THE GP120 GLYCOPROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BINDS TO SENSORY GANGLION NEURONS [J].
APOSTOLSKI, S ;
MCALARNEY, T ;
QUATTRINI, A ;
LEVISON, SW ;
ROSOKLIJA, G ;
LUGARESSI, A ;
CORBO, M ;
SADIQ, SA ;
LEDERMAN, S ;
HAYS, AP ;
LATOV, N .
ANNALS OF NEUROLOGY, 1993, 34 (06) :855-863
[4]
Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age [J].
Araújo, APDC ;
Nascimento, OJM ;
Garcia, OS .
PEDIATRICS, 2000, 106 (03) :art. no.-e35
[5]
Early detection of neurophysiological abnormalities in infection by human immunodeficiency virus [J].
Aznar-Bueno, C ;
Abad-Alegría, F ;
Amiguet, JA .
CLINICAL ELECTROENCEPHALOGRAPHY, 2000, 31 (02) :116-121
[6]
TEMPORAL TRENDS IN THE INCIDENCE OF HTV-1-RELATED NEUROLOGIC DISEASES - MULTICENTER AIDS COHORT STUDY, 1985-1992 [J].
BACELLAR, H ;
MUNOZ, A ;
MILLER, EN ;
COHEN, BA ;
BESLEY, D ;
SELNES, OA ;
BECKER, JT ;
MCARTHUR, JC .
NEUROLOGY, 1994, 44 (10) :1892-1900
[7]
2',3'-DIDEOXYCYTIDINE (DDC) TOXIC NEUROPATHY - A STUDY OF 52 PATIENTS [J].
BERGER, AR ;
AREZZO, JC ;
SCHAUMBURG, HH ;
SKOWRON, G ;
MERIGAN, T ;
BOZZETTE, S ;
RICHMAN, D ;
SOO, W .
NEUROLOGY, 1993, 43 (02) :358-362
[8]
Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors [J].
Blum, AS ;
DalPan, GJ ;
Feinberg, J ;
Raines, C ;
Mayjo, K ;
Cornblath, DR ;
McArthur, JC .
NEUROLOGY, 1996, 46 (04) :999-1003
[9]
CD4 dependence of gp120IIIB-CXCR4 interaction is cell-type specific [J].
Bodner, A ;
Toth, PT ;
Oh, SB ;
Lu, ML ;
Tran, PB ;
Chin, RK ;
Ren, DJ ;
Miller, RJ .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 140 (1-2) :1-12
[10]
Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity [J].
Bodner, A ;
Maroney, AC ;
Finn, JP ;
Ghadge, G ;
Roos, R ;
Miller, RJ .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (06) :1424-1434